Show Search Form

Search Results

registered interest	true false
date	exactly: or between: and
answering body
answering dept id
answering dept short name
answering dept sort name
hansard heading
house id
legislature	pref label
question text
tabling member constituency
tabling member printed
uin
answer	is ministerial correction true false date of answer exactly: or between: and answer text answering member constituency answering member printed grouped question UIN question first answered answering member label
tabling member	label

Search

1661136

registered interest
date	18/09/2023
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Diabetes: Drugs
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, whether he plans to undertake a review of guidance on the prescription of glucagon-like peptide 1 (GLP-1) agonists to patients with type 2 diabetes.
tabling member constituency	Slough
tabling member printed	Mr Tanmanjeet Singh Dhesi
uin	200010
answer	answer is ministerial correction date of answer 16/10/2023 answer text <p>The National Institute for Health and Care Excellence (NICE) is the independent body responsible for providing evidence-based guidance for the National Health Service in England, in line with its established methods and processes.</p><p>NICE’s guideline on the management of type 2 diabetes in adults states that if triple therapy with metformin and 2 other oral drugs is not effective, not tolerated or contraindicated, switching one drug for a glucagon-like peptide 1 agonist should be considered for people who meet the specified criteria.</p><p>NICE is currently updating the drug treatment section of this guideline, which it expects to publish in December 2024. NICE also published final draft guidance on 8 September 2023 which recommends tirzepatide for treating type 2 diabetes alongside diet and exercise in adults who meet the specified criteria. Final guidance on tirzepatide is expected in October 2023.</p> answering member constituency Colchester answering member printed Will Quince question first answered 16/10/2023 13:29:48 answering member 4423 label Biography information for Will Quince
tabling member	4638 label Biography information for Mr Tanmanjeet Singh Dhesi

1661139

registered interest
date	18/09/2023
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Electronic Cigarettes: Young People
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, what the Office for Health Improvement and Disparities timescales are for publishing its response to the consultation entitled Youth vaping.
tabling member constituency	East Londonderry
tabling member printed	Mr Gregory Campbell
uin	199875
answer	answer is ministerial correction date of answer 16/10/2023 answer text <p>The Government will respond to the youth vaping call for evidence in the coming weeks.</p> answering member constituency Harborough answering member printed Neil O'Brien question first answered 16/10/2023 09:52:38 answering member 4679 label Biography information for Neil O'Brien
tabling member	1409 label Biography information for Mr Gregory Campbell

1661142

registered interest
date	18/09/2023
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Sodium Valproate: Packaging
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, with reference to the consultation entitled Original pack dispensing and supply of medicines containing sodium valproate, published in November 2021, what assessment his Department has made of the potential impact of the (a) proposal to always dispense those medicines in the original manufacturer's packaging and (b) other proposals in that consultation on consumers.
tabling member constituency	South Staffordshire
tabling member printed	Sir Gavin Williamson
uin	199958
answer	answer is ministerial correction date of answer 16/10/2023 answer text <p>The amendments to the Human Medicines Regulations 2012 to enable original pack dispensing of medicine and require whole-pack dispensing of medicines containing valproate were signed on 13 September 2023 and come into force on 11 October 2023.</p><p>An impact assessment was published on 19 March 2023 and is available at the following link:</p><p><a href="https://www.legislation.gov.uk/uksi/2023/1015/impacts" target="_blank">https://www.legislation.gov.uk/uksi/2023/1015/impacts</a></p><p>This impact assessment was informed by responses to the consultation that we held on the proposals and sets out the Department’s assessment of the impact of the regulation changes for original pack dispensing and whole pack dispensing of medicines containing valproate.</p> answering member constituency Colchester answering member printed Will Quince question first answered 16/10/2023 13:22:23 answering member 4423 label Biography information for Will Quince
tabling member	4108 label Biography information for Sir Gavin Williamson

1661150

registered interest
date	18/09/2023
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	GP Surgeries
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, whether his Department is taking steps to check GP surgery buildings for reinforced autoclaved aerated concrete (RAAC).
tabling member constituency	Hornsey and Wood Green
tabling member printed	Catherine West
uin	200014
answer	answer is ministerial correction date of answer 17/10/2023 answer text <p>Privately owned primary care estate is not part of the national reinforced autoclaved aerated concrete (RAAC) remediation programme. NHS England has issued RAAC guidance to providers of National Health Service services operating from private premises to advise them to engage with the private landlords who hold the responsibility for surveying and maintaining their own property. In many cases in primary care, the general practitioners are the owners.</p><p>The Department and NHS England have engaged with Community Health Partnerships (CHP) and NHS Property Services (NHSPS) who own the proportion of the primary and community estate in public ownership to understand their RAAC risk and the associated programmes. CHP has not identified any RAAC in its estate. NHSPS has identified three sites that are part of the national programme.</p> answering member constituency Colchester answering member printed Will Quince question first answered 17/10/2023 16:24:52 answering member 4423 label Biography information for Will Quince
tabling member	4523 label Biography information for Catherine West

1661152

registered interest
date	18/09/2023
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Pancreatic Cancer: Mortality Rates
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, what steps his Department is taking to tackle regional disparities in pancreatic cancer survival rates.
tabling member constituency	Ashfield
tabling member printed	Lee Anderson
uin	200015
answer	answer is ministerial correction date of answer 16/10/2023 answer text <p>Reducing inequalities and variation in cancer treatment is a priority for the Government, as is increasing early cancer diagnosis, which is a key contributor to reducing cancer health inequalities and improving survival rates, as set out in the NHS Long Term Plan.</p><p>The pancreatic cancer clinical audit, led by the Royal College of Surgeons, began in 2021, with the first outcomes expected in 2024. A key aim of the audit is to support services in the National Health Service to stimulate improvements in cancer detection, treatment, and outcomes for patients, including improving survival rates.</p><p>To improve early diagnosis, the NHS is implementing non-specific symptom pathways (NSS) for patients who present with vague and non-site specific symptoms which do not clearly align to a tumour type. This includes symptoms of pancreatic cancer. By March 2024, the NSS programme will achieve full population coverage across England for non-specific symptom pathways as set out in the 2023/24 NHS Operational Planning Guidance.</p><p>On 24 January 2023, the Government announced that it will publish a Major Conditions Strategy. The strategy will cover cancer as one of the six conditions that contribute most to morbidity and mortality across the population in England. The strategy will apply a geographical lens to each condition to address regional disparities in health outcomes, supporting the levelling up mission to narrow the gap in healthy life expectancy by 2030.  We published the Major Conditions Strategy Case for Change and Our Strategic Framework on 14 August 2023 which sets out our approach to making the choices over the next five years that will deliver the most value in facing the health challenges of today and of the decades ahead, including for cancer.</p> answering member constituency Colchester answering member printed Will Quince question first answered 16/10/2023 13:53:41 answering member 4423 label Biography information for Will Quince
tabling member	4743 label Biography information for Lee Anderson

1661156

registered interest
date	18/09/2023
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Adrenoleukodystrophy and Thalassaemia: Gene Therapies
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, what assessment he has made of the potential impact of the withdrawal of Bluebird Bio from the (a) UK and (b) European market on access to gene therapy treatment for people with (i) beta thalassemia and (ii) cerebral adrenoleukodystrophy.
tabling member constituency	Blaydon
tabling member printed	Liz Twist
uin	200017
answer	answer is ministerial correction date of answer 16/10/2023 answer text <p>No assessment has been made of the potential impact of the withdrawal of Bluebird Bio from the United Kingdom and European markets on access to gene therapy treatment for people with beta thalassemia and cerebral adrenoleukodystrophy. NHS England continues to make cost-effective treatments available to patients in England as determined by NICE’s technology appraisal and highly specialised technologies programmes.</p> answering member constituency Colchester answering member printed Will Quince question first answered 16/10/2023 14:36:44 answering member 4423 label Biography information for Will Quince
tabling member	4618 label Biography information for Liz Twist

1661158

registered interest
date	18/09/2023
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Rare Diseases: Health Services
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, pursuant to the Answer of 15 May 2023 to Question 183537 on Rare Diseases, for what reason the proposal to provide patients with alert cards was not included in the England Rare Diseases Action Plan 2023; and how his Department plans to ensure adequate co-ordination of care for people with rare conditions in emergency settings.
tabling member constituency	Blaydon
tabling member printed	Liz Twist
uin	200019
answer	answer is ministerial correction date of answer 16/10/2023 answer text <p>There are currently no plans to include a proposal to provide alert cards to patients with rare diseases in the England Rare Diseases Action Plan in the next five years.</p><p>In the Second Progress Report from the Rare Disease Policy Board (2018), NHS England proposed to give every patient with a rare disease an ‘alert card’, which would include information about the patient’s rare disease. This proposal to develop ‘alert cards’ was not progressed at the time due to capacity constraints.</p><p>This proposal has not featured in the subsequent England Rare Diseases Action Plans (2022 and 2023), and NHS England is now focussing on delivering against the actions identified in these new plans. Progress is being made on existing actions to improve coordination of care and awareness of rare diseases amongst all health care professionals, including those who work in emergency settings.</p> answering member constituency Colchester answering member printed Will Quince grouped question UIN 200021 question first answered 16/10/2023 13:10:23 answering member 4423 label Biography information for Will Quince
tabling member	4618 label Biography information for Liz Twist

1661160

registered interest
date	18/09/2023
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Rare Diseases: Health Services
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, pursuant to the Answer of 15 May 2023 to Question 183537 on Rare Diseases, whether he plans to include the proposal to provide alert cards to patients with rare diseases in the England Rare Diseases Action Plan in the next five years.
tabling member constituency	Blaydon
tabling member printed	Liz Twist
uin	200021
answer	answer is ministerial correction date of answer 16/10/2023 answer text <p>There are currently no plans to include a proposal to provide alert cards to patients with rare diseases in the England Rare Diseases Action Plan in the next five years.</p><p>In the Second Progress Report from the Rare Disease Policy Board (2018), NHS England proposed to give every patient with a rare disease an ‘alert card’, which would include information about the patient’s rare disease. This proposal to develop ‘alert cards’ was not progressed at the time due to capacity constraints.</p><p>This proposal has not featured in the subsequent England Rare Diseases Action Plans (2022 and 2023), and NHS England is now focussing on delivering against the actions identified in these new plans. Progress is being made on existing actions to improve coordination of care and awareness of rare diseases amongst all health care professionals, including those who work in emergency settings.</p> answering member constituency Colchester answering member printed Will Quince grouped question UIN 200019 question first answered 16/10/2023 13:10:23 answering member 4423 label Biography information for Will Quince
tabling member	4618 label Biography information for Liz Twist

1661161

registered interest
date	18/09/2023
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Rare Diseases: Health Services
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, whether the needs of people affected by rare conditions will be considered in the development of the Major Conditions Strategy; and what steps his Department is taking to ensure that the overlapping needs of individuals with (a) rare conditions and (b) major conditions covered in the strategy will be adequately met.
tabling member constituency	Blaydon
tabling member printed	Liz Twist
uin	200022
answer	answer is ministerial correction date of answer 16/10/2023 answer text <p>The Major Conditions Strategy will set out a vision for how systems can be better organised around patients, rather than in silos around single diseases. Support and management for people with multiple conditions will increasingly require the management of complexity and moving from a single condition approach. The National Health Service will need to adapt to manage the complexity of multiple conditions with the consequent need to co-ordinate clinical support across primary, community and secondary care.</p> answering member constituency Colchester answering member printed Will Quince question first answered 16/10/2023 13:47:37 answering member 4423 label Biography information for Will Quince
tabling member	4618 label Biography information for Liz Twist

1661186

registered interest
date	18/09/2023
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Department of Health and Social Care: General Dental Council
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, whether Ministers in his Department have met with representatives of the General Dental Council in the last 12 months.
tabling member constituency	St Albans
tabling member printed	Daisy Cooper
uin	200030
answer	answer is ministerial correction date of answer 16/10/2023 answer text <p>Ministers have met with representatives of the General Dental Council in the last 12 months. Ministerial meetings with external organisations are routinely published on GOV.UK.</p> answering member constituency Harborough answering member printed Neil O'Brien question first answered 16/10/2023 13:48:06 answering member 4679 label Biography information for Neil O'Brien
tabling member	4769 label Biography information for Daisy Cooper